88774 Federal Register / Vol. 89, No. 217 / Friday, November 8, 2024 / Notices 

and vendors, who have suffered cancers 

and other designated illnesses as a 

result of exposures sustained in the 

production and testing of nuclear 

weapons. 

Executive Order 13179, issued on 

December 7, 2000, delegated authorities 

assigned to ‘‘the President’’ under the 

Act to the Departments of Labor, Health 

and Human Services, Energy and 

Justice. The Department of Health and 

Human Services (DHHS) was delegated 

the responsibility of establishing 

methods for estimating radiation doses 

received by eligible claimants with 

cancer applying for compensation. 

NIOSH is applying the following 

methods to estimate the radiation doses 

of individuals applying for 

compensation. 

In performance of its dose 

reconstruction responsibilities under 

the Act, NIOSH is providing voluntary 

interview opportunities to claimants (or 

their survivors) individually and 

providing them with the opportunity to 

assist NIOSH in documenting the work 

history of the employee by 

characterizing the actual work tasks 

performed. In addition, NIOSH and the 

claimant may identify incidents that 

may have resulted in undocumented 

radiation exposures, characterizing 

radiological protection and monitoring 

practices, and identify co-workers and 

other witnesses as may be necessary to 

confirm undocumented information. In 

this process, NIOSH uses a computer 

assisted telephone interview (CATI) 

system, which allows interviews to be 

conducted more efficiently and quickly 

as opposed to a paper-based interview 

instrument. Both interviews are 

voluntary and failure to participate in 

either or both interviews will not have 

a negative effect on the claim, although 

voluntary participation may assist the 

claimant by adding important 

information that may not be otherwise 

available. 

NIOSH uses the data collected in this 

process to complete an individual dose 

reconstruction that accounts, as fully as 

possible, for the radiation dose incurred 

by the employee in the line of duty for 

DOE nuclear weapons production 

programs. After dose reconstruction, 

NIOSH also performs a brief, voluntary 

final interview with the claimant to 

explain the results and to allow the 

claimant to confirm or question the 

records NIOSH has compiled. This will 

also be the final opportunity for the 

claimant to supplement the dose 

reconstruction record. 

At the conclusion of the dose 

reconstruction process, the claimant 

submits a form to confirm that the 

claimant has no further information to 

provide to NIOSH about the claim at 

this time. The form notifies the claimant 

that signing the form allows NIOSH to 

forward a dose reconstruction report to 

DOL and to the claimant, and closes the 

record on data used for the dose 

reconstruction. Signing this form does 

not indicate that the claimant agrees 

with the outcome of the dose 

reconstruction. The dose reconstruction 

results will be supplied to the claimant 

and to the DOL, the agency that will 

utilize them as one part of its 

determination of whether the claimant 

is eligible for compensation under the 

Act. 

CDC requests OMB approval for an 

estimated annual 3,900 burden hours. 

There is no cost to respondents other 

than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Claimant ............................................ Initial Interview ................................. 3,600 1 1 3,600 

Claimant ............................................ Conclusion Form OCAS–1 ............... 3,600 1 5/60 300 

Total ........................................... ........................................................... ........................ ........................ ........................ 3,900 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25987 Filed 11–7–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–25–1268; Docket No. CDC–2024– 

0093] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Drug Overdose 

Surveillance and Epidemiology (DOSE). 

This data collection is designed to 

facilitate rapid identification and 

tracking of Emergency Department (ED) 

data on eight drug overdose indicators. 

DATES: CDC must receive written 

comments on or before January 7, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0093 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 217 / Friday, November 8, 2024 / Notices 88775 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Drug Overdose Surveillance and 

Epidemiology (DOSE) (OMB Control No. 

0920–1268, Exp. 9/30/2025)— 

Revision—National Center for Injury 

Prevention and Control (NCIPC), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

In 2022, a total of 107,941 drug 

overdose deaths occurred, 

corresponding to an age-adjusted rate of 

32.6 per 100,000 population, quadruple 

from the 2002 rate (8.2). From 2021 to 

2022, the synthetic opioid-involved 

death rate other than methadone 

increased 4.1%, from 21.8 to 22.7 per 

100,000. The psychostimulant-involved 

age-adjusted death rate increased more 

than 34 times, from 0.3 in 2002 to 10.4 

in 2022, and two states had a significant 

increase in non-fatal overdoses between 

2023 and 2024. In response to the 

growing severity of the opioid overdose 

epidemic, the US government declared 

the opioid overdose epidemic a public 

health emergency (PHE) on October 26, 

2017. The opioid overdose epidemic is 

one of the U.S. Department of Health 

and Human Services (HHS) top 

priorities. In 2021, HHS expanded their 

Overdose Prevention Strategy to focus 

on four strategic priorities: primary 

prevention, harm reduction, evidencebased treatment, and recovery support. 

Drug Overdose Surveillance and 

Epidemiology (DOSE) 2.0 is made 

possible because the vast majority of the 

participating health departments are 

already rapidly collecting extensive data 

on Emergency Department (ED) visits in 

their jurisdiction and using these data 

for the identification of public health 

concerns including flu and other 

respiratory illnesses, heat-related 

illness, and hurricane-related health 

issues. DOSE 1.0 ensured participating 

jurisdictions use their data to track 

suspected overdoses by providing 

participating jurisdictions standardized 

definitions of ED visits involving all 

drug, all opioid, heroin and all 

stimulant overdoses. To further advance 

overdose surveillance, for DOSE 2.0, 

CDC added four additional drug 

indicators—fentanyl, cocaine, 

methamphetamine, and benzodiazepine. 

This facilitates rapid identification and 

tracking of ED data on a total of eight 

drug overdose indicators. 

Also, no single ED surveillance 

system has national coverage, but 

almost all participating health 

departments use one of three systems— 

the NSSP BioSense System, local ED 

syndromic surveillance, or ED/inpatient 

hospital discharge overdose data files. 

DOSE 2.0 integrates data across these 

three types of ED surveillance to quickly 

build a national surveillance system 

while leveraging existing ED data 

collection efforts. DOSE 2.0 can use data 

across the three types of ED surveillance 

systems because the key data 

requirement is the ability to detect 

change over time (e.g., data consistently 

collected within the jurisdiction 

overtime) and not comparability across 

participating health departments (e.g., 

same data collection methods deployed 

across state health departments 

overtime). 

CDC is requesting OMB approval for 

three years with an annual estimated 

burden of 655 hours. There is no cost to 

respondents other than their time to 

participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Responses 

per 

respondent 

Average 

burden per 

response 

(hours) 

Total 

annual 

burden 

(hours) 

Participating health departments sharing aggregate data 

from NSSP BioSense.

Rapid ED overdose data 

form.

45 12 0.5 270 

Participating health departments sharing aggregate data 

from local syndromic data file.

Rapid ED overdose data 

form.

3 12 3 108 

Participating health department sharing finalized ED and 

inpatient hospitalization aggregate data on total ED/inpatient hospitalization visits, and metadata on a yearly 

basis.

ED and hospitalization discharge overdose data 

form.

32 1 3 96 

Participating health department sharing finalized aggregate data on total inpatient hospitalization visits, and 

metadata on a yearly basis.

Inpatient hospitalization discharge overdose data 

form.

3 1 2 6 

Participating health department sharing line-level ED/inpatient hospitalization discharge data (.csv) on drug 

overdose-related visits (i.e., any visit with an ICD–10– 

CM code between T36–T50, including all intents, encounters, underdosing, and adverse effects.

.............................................. 35 1 5 175 


ddrumheller on DSK120RN23PROD with NOTICES1
88776 Federal Register / Vol. 89, No. 217 / Friday, November 8, 2024 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondent Form name Number of 

respondents 

Responses 

per 

respondent 

Average 

burden per 

response 

(hours) 

Total 

annual 

burden 

(hours) 

Total ............................................................................ .............................................. .................... .................... .................... 655 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25989 Filed 11–7–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–25–1105; Docket No. CDC–2024– 

0092] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled One Health 

Harmful Algal Bloom System 

(OHHABS). This data collection is 

designed to support the understanding 

and prevention of Health Harmful Algal 

Blooms (HAB) and HAB-associated 

illnesses. 

DATES: CDC must receive written 

comments on or before January 7, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0092 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments through 

the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

One Health Harmful Algal Bloom 

System (OHHABS) (OMB Control No. 

0920–1105, Exp. 11/30/2025)— 

Revision—National Center for Emerging 

and Zoonotic Infectious Diseases 

(NCEZID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

Harmful algal blooms (HABs) are the 

rapid growth of algae or cyanobacteria 

(also called blue-green algae) that can 

cause harm to people, animals, or the 

local ecology. Algal toxins from harmful 

algal blooms (HABs) include some of 

the most potent natural chemicals; these 

toxins can contaminate surface water 

used for recreation and drinking, as well 

as food sources. HABs pose a threat to 

both humans and animals. Human and 

animal illnesses from exposures to 

HABs in fresh and marine waters have 

been documented in the United States. 

Animal illness may be an indicator of 

bloom toxicity; thus, it is necessary to 

provide a One Health approach for 

reporting HAB-associated illnesses and 

events. 

OHHABS was approved for data 

collection in 2016. The system was 

launched in June 2016 along with a CDC 

HAB-associated illnesses website to 

provide more information for the 

general public about potential illnesses 

and to share resources for HAB 

awareness and OHHABS with public 

health partners. Since 2016, CDC has 

provided technical assistance and 

training to states and territories 

interested in OHHABs and worked with 

contractors to implement new features 

for OHHABS. 

CDC estimates the annualized burden 

hours based on historical data of the 

actual number of respondents to 

OHHABS. Specifically, CDC estimates 

300 annual environmental reports, 90 

human reports, and 130 animal reports, 

by taking the average number of reports 

submitted to OHHABS during 2018– 

2022. CDC had six employees use mock 


ddrumheller on DSK120RN23PROD with NOTICES1

I I I I